North America Glucagon-like Peptide-1 Agonists Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

North America Glucagon-like Peptide-1 Agonists Market Trends and Insights

Type-2 Diabetes Prevalence Escalation

The Centers for Disease Control and Prevention documented 38.4 million Americans living with diabetes in 2024, of whom up to 95% have type 2 diabetes. Rising adolescent incidence extends lifetime drug utilization horizons, creating multi-decade revenue streams. The American Diabetes Association’s 2025 standards place GLP-1 receptor agonists immediately after metformin for high-risk patients, expanding the eligible pool by roughly 12 million adults ^{[1]American Diabetes Association, “Standards of Care 2025,” diabetes.org}. Canada shows a parallel rise, with 11.9 million citizens affected by diabetes or pre-diabetes in 2024. Younger onset increases cardiovascular risk over time, which strengthens the clinical argument for early incretin therapy. Together, these epidemiologic shifts add positive pressure to prescription growth through 2031.

Obesity-Focused Label Expansions and Coverage Gains

The FDA cleared semaglutide for cardiovascular risk reduction in March 2024, which unlocked Medicare Part D coverage because the drug now treats a covered cardiovascular condition rather than obesity alone. In November 2024, the Centers for Medicare & Medicaid Services proposed rules that would extend anti-obesity drug benefits to 7.4 million beneficiaries, opening an untapped payer segment ^{[2]Centers for Medicare & Medicaid Services, “Proposal to Expand Access to Obesity Medications,” cms.gov}. Commercial insurers follow a mixed strategy: some demand 12-week lifestyle documentation, whereas others waive step therapy after high-risk scores are confirmed. Employer self-insured plans adopt GLP-1 carve-outs, attracted by modeled 120% returns on investment tied to absenteeism reductions. Expanded benefits sharpen demand visibility and enhance revenue predictability for manufacturers.

Cardiometabolic Outcome-Based Guideline Inclusion

Cardiology, nephrology, and endocrinology societies now unanimously endorse GLP-1 receptor agonists for cardiovascular risk reduction after the SELECT and SOUL trials demonstrated 20% and 14% event reductions, respectively. The World Health Organization added semaglutide to the 2025 essential medicines list, signaling global consensus ^{[3]World Health Organization, “Essential Medicines List 2025,” who.int}. In the United States, the American College of Cardiology reclassified semaglutide and tirzepatide as first-line agents for patients with established atherosclerotic disease and obesity in 2025. Health-system formularies responded by raising GLP-1 placement to preferred tiers, giving cardiologists a stronger voice in treatment decisions. Shared decision-making now integrates weight control, glycemic management, and cardiovascular benefit, reinforcing the therapeutic value proposition.

Tele-Prescription and DTC Platforms Accelerate Uptake

Virtual platforms compress the care pathway. Hims & Hers recorded an average 48-hour turnaround from web consultation to medication shipment in 2024. Ro’s asynchronous model enrolled over 100,000 patients by mid-2024, demonstrating scalable clinician capacity. Eli Lilly’s LillyDirect integrates telehealth, independent pharmacies, and home delivery across 49 states, capturing 8% of tirzepatide prescriptions by late 2024. Fast fulfillment appeals to patients facing multi-week waits at traditional clinics. Regulatory scrutiny is tightening; however, the FDA issued warning letters to compounding pharmacies marketing semaglutide despite resolved shortages, a move that may narrow gray-market supply. Balanced oversight will determine whether DTC platforms maintain momentum or revert to conventional dispensing.

Drug Cost and Payer Prior-Authorization Hurdles

Wholesale acquisition prices range between USD 935 and USD 1,349 per month in 2026, positioning GLP-1 agonists among the most expensive chronic-care therapies in North America. Pharmacy benefit managers apply layered prior-authorization checks that verify lifestyle modification, body-mass index thresholds, and comorbidity profiles, adding an average 15-day delay to therapy initiation. Prime Therapeutics reported initial denial rates of 42% for GLP-1 requests in 2024, although two-thirds were overturned on appeal with added documentation. High-deductible health plans expose commercially insured patients to USD 150–300 monthly out-of-pocket costs, driving abandonment rates above 30% at first fill. As more outcomes data affirm broader benefits, payers may soften criteria, but cost friction remains the near-term speed limit on market growth.

Periodic API and Pen-Device Shortages

Between 2022 and 2024, the FDA shortage database frequently listed Ozempic, Wegovy, Mounjaro, and Zepbound due to pen-device bottlenecks. Novo Nordisk allocated USD 6 billion to scale its Chartres, France, plant and USD 4.1 billion for a new facility in Clayton, North Carolina, aiming to add 50% more capacity by 2027. Eli Lilly is investing USD 9 billion across four sites to double tirzepatide output by late 2026. While shortages eased in late 2024, recurrent demand spikes could reappear until new lines reach commercial volumes. Interim gaps invite compounded-product alternatives that challenge quality oversight.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug: Mounjaro’s Dual Agonism Redefines Therapeutic Efficacy

The North America Glucagon-like Peptide-1 agonists market size for Mounjaro is poised to expand at a 16.87% CAGR, fueled by 22.5% mean weight reduction in SURMOUNT-1 and superior glycemic control relative to semaglutide. Ozempic kept a 49.8% North America Glucagon-like Peptide-1 agonists market share in 2025 because of its first-mover advantage and positive cardiovascular data from the SELECT trial. Wegovy and Zepbound drew 18% combined revenue in 2025, their growth grounded in fresh cardioprotective labeling and pending Medicare coverage finalization. Rybelsus caters to needle-averse patients, though its fasting rule curbs adherence; orforglipron seeks to remove that barrier when submitted for approval in 2026.

Pipeline candidates are re-shaping competitive contours. Cagrisema, the semaglutide–cagrilintide fixed-ratio mix, reported 27.1% weight loss in REDEFINE-2, while survodutide and retatrutide advance multi-agonist strategies. Trulicity, once a category mainstay, is slipping under patent-expiry shadow as biosimilars queue for 2027. Legacy options such as liraglutide and exenatide are eroding at 6% annually as prescribers pivot to weekly agents with stronger cardiometabolic evidence.

By Route of Administration: Oral Agents Gain Momentum

Subcutaneous injectables command 85.6% of prescriptions due to weekly dosing and well-documented cardiovascular and renal outcomes. Their user-friendly pens, concealed needles, and auto-injector designs help blunt needle aversion. Semaglutide also demonstrated a 24% reduction in kidney disease progression in the FLOW study, reinforcing clinician confidence.

Oral formulations grow at a 14.65% CAGR as patients seek needle-free options. Rybelsus posted USD 1.9 billion global sales in 2024, and its October 2025 cardiovascular indication approval heightened primary-care adoption. The North America Glucagon-like Peptide-1 agonists market size for oral agents is expected to accelerate once orforglipron reaches the market. Patient-preference surveys reveal that 40% of eligible individuals refused injections in favor of tablets when equally effective choices exist. As adherence obstacles, namely, fasting requirements, are ironed out, oral uptake will chip away at injectable dominance.

By Indication: Obesity Applications Outpace Diabetes

Obesity and weight-management prescriptions represent the fastest-moving segment, advancing at a 13.45% CAGR on the heels of expanded labeling and payer adoption. The FDA authorized Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease, allowing Medicare Part D reimbursement, which reshapes the North America Glucagon-like Peptide-1 agonists market size equation for this indication. Commercial insurers layer tiered co-insurance but loosen step therapy once comorbid cardiovascular risk is documented. 

Type-2 diabetes still represents 58.89% of revenue in 2025, underpinned by long-standing guideline status and glycemic efficacy. Cardiovascular risk-reduction prescriptions accounted for 12% of 2025 volume yet should reach 22% by 2031, following cardiology guideline alignment. Specialty-level diffusion is visible: cardiologists wrote 8% of GLP-1 scripts in 2024, up from 2% two years earlier. Nephrologists are next in line as FLOW results get embedded into chronic kidney disease management algorithms.

By Distribution Channel: DTC Platforms Disintermediate Traditional Pharmacy Networks

Retail and chain pharmacies held a 54.23% share in 2025; however, DTC platforms climbed at a 15.82% CAGR by promising rapid access and transparent pricing. Hims & Hers enrolled over 40,000 patients in five months, using compounded semaglutide priced 50% below branded injectable alternatives. Eli Lilly’s LillyDirect demonstrates how originators can bypass traditional pharmacy benefit managers while retaining reimbursement acceptance.

Hospital pharmacies dispense 18% of volume, primarily during inpatient stays for hyperglycemia or acute cardiovascular care. They now negotiate value-based contracts linking GLP-1 use to reduced readmission penalties. Retailers combat margin compression by developing virtual consultation arms, yet sustained compounded-product availability hinges on the FDA shortage status. Enforcement actions in late 2024 narrowed compounded supply and may push DTC platforms toward branded sourcing, adding cost pressure but preserving market momentum.

Geography Analysis

The United States leads the region, generating 85.43% of 2025 revenue. Obesity prevalence reached 41.9% among adults during 2017–2020 and is forecast to hit 60.6% by 2050 if trends persist. Employer self-insured plans, covering 64% of workers, model tangible productivity savings, which spur benefit adoption even when PBM rebates remain opaque. If finalized, the 2026 CMS rule will add 7.4 million public beneficiaries, transforming payer mix and volume forecasts. State Medicaid coverage remains fragmented, with unrestricted access in 23 states versus outright exclusions in nine, creating access deserts for low-income populations. FDA approval of oral semaglutide for cardiovascular risk reduction in October 2025 enabled Medicare Advantage plans to list the drug under cardiovascular codes, bypassing obesity exclusions.

Canada exhibits policy heterogeneity due to provincial autonomy. Ontario funds semaglutide and dulaglutide for diabetes under the Ontario Drug Benefit, yet limits Wegovy access to body-mass index above 35 kg/m² with comorbid conditions. Quebec added Wegovy in March 2024, while British Columbia still excludes anti-obesity GLP-1 therapies. CADTH issued positive cost-effectiveness opinions for semaglutide and tirzepatide under diabetes indications, but budget constraints slow uniform uptake. Private insurers cover 78% of employer plans, though step-therapy and prior-authorization add an average 30-day lag before therapy commencement.

Mexico is poised for a 15.10% CAGR through 2031. Nearshoring brings fill-finish plants closer to North American demand, and COFEPRIS utilizes accelerated pathways for biosimilars, as evidenced by Biocon’s liraglutide approval in 2024. Public payers IMSS and ISSSTE reimburse GLP-1 agonists only for diabetes, excluding obesity, yet rising private insurance penetration in the expanding middle class is widening access. Novo Nordisk singled out Mexico as its largest Latin American market in 2024, and Eli Lilly intends to localize manufacturing to bolster regional resilience. Currency fluctuations pose a pricing challenge, but domestic production and biosimilar entry may temper import costs.

Regulatory Landscape

The North American regulatory environment for GLP-1 receptor agonists centers on supply integrity and patient safety as branded products gain market prominence. In April 2026, the FDA clarified the conditions under which 503A and 503B compounders may qualify for exemptions, which points to tighter compliance expectations for compounded semaglutide and related APIs. In 2026, the White House issued a Section 232 action on pharmaceutical imports, adding tariff compliance mechanisms that affect GLP-1 supply chain costs. Health Canada approved a generic semaglutide injection in 2026, supporting lower-cost pathways in the region, while the United States continues to emphasize domestic manufacturing incentives and enforcement to improve supply stability.

Market Opportunities and Future Outlook

Supply-chain reconfiguration is creating near-term whitespace in high-complexity peptide API capacity and compliant fill-finish that can support established injectables and next-wave oral agents. Large manufacturers are anchoring this shift with multibillion-dollar site investments tied to tirzepatide and the oral pipeline, while CDMOs are consolidating peptide capabilities, including CordenPharma's 2026 acquisition of AmbioPharm to expand U.S.-based peptide API options. Commercial opportunity is strengthening around payer acceptance and channel redesign for obesity and cardiometabolic use cases, supported by labeling and policy actions already in motion. The March 2024 FDA clearance of semaglutide for cardiovascular risk reduction enabled Medicare Part D reimbursement, and the November 2024 CMS proposal to extend anti-obesity drug benefits to 7.4 million beneficiaries highlights a defined public payer pool under active rulemaking. As enforcement narrows the compounded gray market when shortages resolve, brand-sponsored digital pathways such as LillyDirect, along with online and direct-to-consumer fulfillment, are gaining a clearer lane to scale within compliant dispensing and reimbursement frameworks.